HyperAcute Pancreas: Phase III started

NewLink began an open-label Phase III trial to compare HyperAcute Pancreas plus standard of care (SOC; 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin) vs. SOC alone in about 280 patient...